RBD Longitudinal as Prognostic for PD

The University of Texas Health Science Center, Houston164 enrolled

Overview

* Purpose - to validate a combination of biological and clinical markers in the rapid-eye-movement (REM) sleep behavior disorder (RBD) population as indicative of the pre-symptomatic stage of Parkinson's disease (PD). * Procedures - All subjects (RBD diagnosis and controls) will have 1) a medical and neuro history and physical including videotape of movements, 2) neuropsychological testing, 3) a sleep study, 4) olfactory testing, 5) blood draw for serum testing , 6) functional MRI. All of these procedures are often performed clinically in the diagnosis of PD. Enrollment of subjects with PD is complete. Any testing performed prior to enrollment as part of the clinical evaluation may be used in place of repeating the procedure for the study. Subjects will be followed for 5 years. It is hypothesized that a 5 year follow up may capture a significant number of pre-Parkinson's subjects who will be diagnosed. Subjects may be offered a repeat enrollment after 5 years.

Enrollment of PD and PS cohorts is complete. Currently enrolling only confirmed RBD and Controls.

Study Type

OBSERVATIONAL

Enrollment

164

Conditions

Rapid Eye Movement Sleep Behavior Disorder

Eligibility

Sex: ALLMin age: 35 YearsMax age: 70 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. 35-70 year old men \& women 2. (1) Diagnosis of idiopathic RBD (see AASM criteria), 2) Normal control or control with a non-neurodegenerative disorder, age and gender-matched to (1) 3. Gives written informed consent 4. Pregnant women are not excluded, but will be identified by HCG. Exclusion Criteria: a A diagnosis of any non-Parkinsonian Neurodegenerative Disease. b. Any unstable or uncontrolled medical or psychiatric condition. c. Parasomnia or RBD not idiopathic, eg., secondary to metabolic derangement or medicine effect. d. Renal (creatinine over 1.6) or hepatic insufficiency (LFT significantly out of range), or a history of significant uncontrolled cardiac disease. e. Significant dementia (MMSE\<25 of 30 or MOCA\<25/30) that would interfere with study procedures or informed consent. f. Any reason which, in the opinion of the PI, would increase the risk or decrease the value of any study procedure. g. fMRI will not be performed for anyone for whom the screening questionnaire indicates is ineligible for MRI imaging.

Outcomes

Primary Outcomes

Identify the key cognitive and non-motor characteristics for early PD diagnosis

periodically performed set of clinical and imaging parameters suspected to be linked to PD to see if, as a group, these parameters could identify those at risk for motor symptoms of PD before these symptoms develop.

Time frame: 5 years

Secondary Outcomes

Further characterize the sleep behavior patterns, olfactory function, and neurologic assessments of subjects longitudinally, over 5 years, within each group of patients.

perform baseline sleep study, olfactory testing and clinical neurologic exam followed by periodically performed set of clinical parameters.

Time frame: 5 years

functional MRI of the brain and eye tracking testing, identification of distinct features in PD

Perform fMRI at baseline and at 2 years followed by periodically performed set of clinical parameters.

Time frame: beginning of study and at 2 years

identify key fluid-based PD-associated molecular markers that identify disease state or progression

parameters within blood may be present \& measurable well before motor symptoms of PD are seen.

Time frame: 5 years

RBD Longitudinal as Prognostic for PD

Overview

Conditions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes